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Abstract
Physiological changes necessitate the use of pregnancy-specific reference ranges for TSH and FT4 to diagnose thyroid
dysfunction during pregnancy. Although many centers use fixed upper limits for TSH of 2.5 or 3.0 mU/L, this comment
describeds new data which indicate that such cut-offs are too low and may lead to overdiagnosis or even overtreatment.
The new guidelines of the American Thyroid Association have considerably changed recommendations regarding thyroid
function reference ranges in pregnancy accordingly. Also a stepwise approach to interpreting these guidelines is
discussed as well as the relevant role of FT4 in diagnosis.
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Background
Thyroid physiology changes during pregnancy and this
necessitates the use of pregnancy-specific reference
ranges for TSH and FT4 in order to adequately diagnose
gestational thyroid disease [1]. Currently, many centers use
a reference range for TSH with an upper limit of 2.5 mU/l
in the first trimester and 3.0 mU/l in the second or third
trimester to diagnose subclinical and overt hypothyroidism.
This is based on outdated international guidelines from
the American Thyroid Association (2011), the Endo-
crine Society (2012) and the European Thyroid Associ-
ation (2014) [2–4]. Although each of these guidelines
recommend to calculate lab-specific reference ranges for
TSH and FT4, many centers do not have such reference
ranges available. Instead, most centers adhere to the
former second recommendation which is that, in the ab-
sence of lab-specific reference ranges, fixed upper limits
for TSH (2.5 mU/l in the first and 3.0 mU/l in the sec-
ond and third trimester) can be used. However, recent
studies have indicated that these cut-offs are too low
and may lead to overdiagnosis and unnecessary treat-
ment, or even overtreatment. Based on some important
findings discussed below, the 2017 American Thyroid
Association guidelines have updated the recommenda-
tions on the upper limit for TSH during pregnancy.
Main text
Various studies have demonstrated that with the use of
fixed TSH upper limits, 8–28% of pregnant women have
a TSH concentration that is considered too high [5, 6].
These numbers are much larger than the roughly 3–4%
that would have a too high TSH if population-based refer-
ence ranges would be used to define the upper limits for
TSH. Medicalization of a group of women as large as 8–
28% is unwarranted, unsustainable and likely to cause
more harm than benefit. Further data indicate that the
upper limit for TSH should be higher. By summarizing
14 studies that calculated population-based pregnancy-
specific reference ranges for TSH and/or FT4, our group
was able to show that in more than 90% of all studies, the
upper limit for TSH was above 2.5 or 3.0 mU/l [7]. More-
over, the few studies performed in a population that
was proven to be iodine sufficient report an upper limit
for TSH of 4.04 and 4.34 mU/l [7], however, the effects
of population iodine status on reference range values
remains to be studied. Interestingly, a large randomized
controlled trial that screened approximately 100.00
pregnant women for subclinical hypothyroidism and
hypothyroxinemia using the fixed TSH cut-offs [8] had
to amend its protocols because the TSH upper limit
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turned out to be 4.0 mU/l after roughly 15.000 women
were screened.
The 2017 ATA guidelines [9] now recommend the
following:
1) Calculate pregnancy-specific and lab-specific references
ranges for TSH and FT4
2) If 1 is not possible, adopt a reference range from
the literature that is derived using a similar assay
and preferably also in a population with similar
characteristics (i.e. ethnicity, BMI, iodine status)
3) If 1 and 2 are not possible, deduct 0.5 mU/l from the
non-pregnancy reference range (which in most
centers would results in a cut-off of roughly 4.0 mU/l)
My interpretation of these recommendations is prob-
ably more strict than that of most endocrinologists or
gynecologists. Lab-specific reference ranges better identify
women with gestational thyroid dysfunction than refer-
ence ranges defined by another methodology [7, 10].
Calculating lab-specific references ranges is not difficult
and every hospital in which prenatal care is provided
would be able to perform a good study at very low
costs (i.e. less than a few thousand euro/GBP), particularly
when collaborating with the clinical chemistry department.
Adequate reference ranges can be obtained by selecting at
least 400 pregnant women with a singleton pregnancy, free
of pre-existing thyroid disease, that do not use thyroid inter-
fering medication, that did not undergo IVF treatment and
are TPOAb negative [7]. Therefore, I believe that if a center
does not have lab-specific reference ranges readily available,
physicians should not automatically move to step 2 or 3 of
the guideline recommendations, but try to obtain lab-
specific reference ranges. Calculating such reference ranges
will instantly improve the quality of clinically diagnosing
thyroid dysfunction in pregnancy. When specific expert-
ise is missing, groups involved in the field of thyroid
and pregnancy (including our group) would be more
than willing to share their experience.
Although it seems clear that fixed upper TSH limits of
2.5 mU/l or 3.0 mU/l can no longer be considered adequate,
the new ATA guidelines seem to make one exception. A
new recommendation indicates that levothyroxine treatment
can be considered for a TSH above the reference range in
TPOAb negative women, while for TPOAb positive women
treatment can be considered from a TSH above 2.5 mU/L
[9]. This is based on data from observational studies show-
ing that there is a higher risk of miscarriage and premature
delivery in TPOAb positive women with high-normal TSH
concentrations (i.e. above roughly 2.5 mU/L). However, new
studies published only shortly after release of the new guide-
lines could not show any beneficial effect of levothyroxine
treatment for women with a TSH above 2.5 mU/L, but
did find beneficial effects for women with a TSH above
4.0 mU/L [11–13]. However, larger studies are needed
to confirm these findings and identify the true TSH
concentration from which the outcome of clinical adverse
outcomes is increased.
While much focus has gone into defining the upper
limit for TSH, the definition of thyroid dysfunction is
also dependent on the FT4 concentration. For example,
in a hypothetical patient with a TSH of 5.5 mU/l, the
FT4 concentration will decide whether there is overt
hypothyroidism or subclinical hypothyroidism. The dis-
tinction between these clinical disease entities can have
major consequences for the clinical work-up and ap-
proach. Although some studies have casted doubt about
the validity of FT4 immunoassays during pregnancy, it is
important to realize that the vast majority of patients
present during early pregnancy during which the assay
interference by thyroid hormone binding proteins is not
relevant (only relevant during the third trimester). More-
over, lab-specific reference ranges for FT4 will still cor-
rectly identify women with true low or true high FT4
given that there is a high correlation between FT4 con-
centrations measured by immunoassays and after disequi-
librium dialysis or with LCMS [1]. The alternative of
increasing the non-pregnancy limits for total T4 by 150%
does not seem viable given the gestational age specific
changes and lack of association of total T4 with adverse
outcomes [1, 14].
Conclusions
In conclusion, any hospital or physician that is still using
the 2.5 or 3.0 mU/l cut-off for TSH during pregnancy
should re-evaluate their practice. When doing so, I strongly
advise to start a study to define lab-specific references
range for TSH and FT4. If there is absolutely no possibility
to do so, a literature search to identify and adopt reference
ranges from a similar lab would be the best alternative.
Although it is highly likely that the use of the 2.5 and
3.0 mU/L cut-offs can lead to overtreatment, future
studies are needed to identify if levothyroxine treatment
in women with a TSH or FT4 outside of population-based
reference ranges has beneficial effects.
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